We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
从价值医疗视角探讨晚期卵巢癌多腺苷二磷酸 核糖聚合酶抑制剂维持治疗的用药选择.
- Authors
苏 怡; 杨国旺; 杨雯靖
- Abstract
Four kinds of poly adenosine diphosphate ribose polymerase (PARP) inhibitors are currently approved in China for maintenance therapy of advanced ovarian cancer, and the drug accessibility and affordability have been greatly improved. With the widespread use of PARP inhibitors, clinicians have new challenges in guiding individualized clinical practice based on guideline recommendations. The thesis discusses the medication for PARP inhibitors maintenance therapy in advanced ovarian cancer from the perspective of value medical treatment (efficacy, safety and accessibility), with the aim of providing guidance for clinical medication.
- Subjects
CHINA; POLY ADP ribose; DRUG accessibility; OVARIAN cancer; POLY(ADP-ribose) polymerase; THERAPEUTICS
- Publication
Evaluation & Analysis of Drug-Use in Hospitals of China, 2023, Vol 23, Issue 8, p897
- ISSN
1672-2124
- Publication type
Article
- DOI
10.14009/j.issn.1672-2124.2023.08.001